Eli Lilly and Company (LLY)
Eli Lilly's weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels. The company now has the full clinical trial data required to start filing for approvals of the drug for chronic weight management with global regulators.
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial, orforglipron caused weight loss that missed Wall Street's expectations and came below what Novo Nordisk reported for its oral drug in a separate study.
The Best Stocks to Invest $50,000 in Right Now
Congratulations, you've got $50,000 in unexpected cash! Will you buy a new car?
Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued
Novo Nordisk and Eli Lilly both declined significantly in the last months. This was mainly caused by efficacy uncertainty, further competition and political headwinds. Despite the sell-offs, I currently think just one of the two is a compelling buy, even offering upside potential of up to 77%.
The Big 3: LLY, BA, CVS
Dan Deming considers Friday's trading action after Jerome Powell's Jackson Hole speech "remarkable." On stocks he's watching ahead, he expects Eli Lilly (LLY) to rebound off a significant sell-off, Boeing (BA) to soar on its financial recovery and aircraft backlog, and CVS Health (CVS) to capture more market share in the pharma space.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Pharmaceuticals Industry Analysis: Eli Lilly Tops My Tier Two
I invest for long-term total return, focusing on high-quality, dividend-paying industry leaders with strong financials and consistent performance. Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in pharmaceuticals, especially as AI could boost efficiency and profits. My tier-two pharma picks show solid fundamentals, but Eli Lilly stands out for its growth potential, especially in diabetes and weight loss drugs.
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
3 Fantastic Growth Stocks to Buy in August
We're well into the home stretch of 2025. August is more than halfway over.
Eli Lilly: Don't Bet Against This Biotech Powerhouse
Eli Lilly's recent 20% pullback is a buy-the-dip opportunity, as the market overreacted to mixed Orforglipron results. Blockbuster drugs Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% year-over-year, with raised FY2025 guidance. LLY's strategic R&D investments and acquisitions strengthen its innovation pipeline, supporting future growth and product diversification.
Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes
The pricing of weight-loss drugs like Lilly's Zepbound and Novo's Wegovy is a pressure point for investors.
